The discovery of Chagas disease (1908-1909): great successes and certain misunderstandings and challenges

Coura, José Rodrigues

doi:10.1590/0037-8682-0143-2013

Cited by 17 publications

(9 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These insects are of great importance to public health as they are involved in transmission of South American trypanosomiasis, also called Chagas' disease (2) in honor of Carlos Chagas who fi rst described this disease in 1909 (1) (3) (4) .…”

mentioning

confidence: 99%

First report of Rhodnius montenegrensis (Hemiptera, Reduviidae, Triatominae) in the State of Acre, Brazil

Meneguetti

Tojal

Miranda

et al. 2015

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Introduction: This paper reports, for the fi rst time, the presence of Rhodnius montenegrensis in the State of Acre, Brazil. Methods: Two female R. montenegrensis were collected in a dwelling in the rural area of Rio Branco, Acre, Brazil. Results: The occurrence of this species was confi rmed, and the number of Triatominae species in the State of Acre increased from four to fi ve. Conclusions: Further studies should be performed to reach a clearer understanding of the ecology of this arthropod, its possible role in transmitting Chagas' disease and rangeliosis, and its current geographical distribution in the region.

show abstract

mentioning

confidence: 99%

First report of Rhodnius montenegrensis (Hemiptera, Reduviidae, Triatominae) in the State of Acre, Brazil

Meneguetti

Tojal

Miranda

et al. 2015

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

show abstract

“…Despite the fact that the disease was described over a century ago [10] only two drugs are available for Chagas disease treatment, benznidazole and nifurtimox, which were developed over 40 years ago. Both drugs produce significant side effects and low efficacy for the chronic phase of the disease (and extremely poor tolerability).…”

Section: Introductionmentioning

confidence: 99%

Advances in preclinical approaches to Chagas disease drug discovery

Villalta

Rachakonda

2019

Expert Opinion on Drug Discovery

View full text Add to dashboard Cite

Introduction Chagas disease affects 8–10 million people worldwide, mainly in Latin America. The current therapy for Chagas disease is limited to nifurtimox and benznidazole, which are effective in treating only the acute phase of the disease but with severe side effects. Therefore, there is an unmet need for new drugs and for the exploration of innovative approaches which may lead to the discovery of new effective and safe drugs for its treatment. Areas covered The authors report and discuss recent approaches including structure-based design that have led to the discovery of new promising small molecule candidates for Chagas disease which affect prime targets that intervene in the sterol pathway of T. cruzi. Other trypanosome targets, phenotypic screening, the use of artificial intelligence and the challenges with Chagas disease drug discovery are also discussed. Expert opinion The application of recent scientific innovations to the field of Chagas disease have led to the discovery of new promising drug candidates for Chagas disease. Phenotypic screening brought new hits and opportunities for drug discovery. Artificial intelligence also has the potential to accelerate drug discovery in Chagas disease and further research into this is warranted.

show abstract

“…Berenice who lived in a house infested with P. megistus with a feverish condition and found in her blood the protozoan T. cruzi, describing the disease in 1909 [8]. Later, Carlos Chagas wrote about acute and chronic forms of the disease (1911) and the life cycle of T. cruzi (1931) [9], among other topics.…”

Section: Introductionmentioning

confidence: 99%

Eco-Epidemiology of Chagas Disease in Chile

Lambarri¹,

Cifuentes²,

Ayala³

et al. 2018

Chagas Disease - Basic Investigations and Challenges

View full text Add to dashboard Cite

There are four vector species of Chagas disease in Chile: Triatoma infestans, responsible for the domestic cycle; Mepraia spinolai, the main wild vector; and M. gajardoi and M. parapatrica, two coastal wild species whose importance as vectors is not well known. They are species of dry environments of the central-north region of Chile, whose best predictors of distribution are warm average temperatures and low rainfall. They are found in rock quarries, nests of birds, and small mammals, and T. infestans has sylvatic foci associated with a Bromeliaceae species. While human blood represents 70% of the diet of T. infestans, in M. spinolai this value is 7%, which means that a large part of Chagas disease in Chile is due to T. infestans. However, all species have high percentages of T. cruzi infection. Chagas disease in Chile follows the distribution of T. infestans, and although the cycle of domestic transmission by this vector is interrupted, there is still a constant prevalence and mortality and ascending incidences. Models predict that although climate change will not vary greatly the north-south distribution of vectors, it could increase the reproductive number of the disease, increasing risk areas of Chagas disease.

show abstract

The discovery of Chagas disease (1908-1909): great successes and certain misunderstandings and challenges

Cited by 17 publications

References 5 publications

First report of Rhodnius montenegrensis (Hemiptera, Reduviidae, Triatominae) in the State of Acre, Brazil

First report of Rhodnius montenegrensis (Hemiptera, Reduviidae, Triatominae) in the State of Acre, Brazil

Advances in preclinical approaches to Chagas disease drug discovery

Eco-Epidemiology of Chagas Disease in Chile

Contact Info

Product

Resources

About